에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

HealthEquity

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FIVE

STNE

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 월스트리트는 시그넷 주얼러스(NYSE:SIG)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.

수요일 주목해야 할 주식: 윌리엄스-소노마, 헬스에퀴티, 시그넷, 스톤코 및 파이브 빌로우

Healthequity,Headquarters,In,Draper,,Utah,,Usa,,June,25,,2023.,Healthequity,

Guidance

Health Care

Analyst Ratings

Movers

Insurance

화요일(18일) 장이 마감된 후 헬스에퀴티(NASDAQ:HQY)는 4분기 실적을 발표했고 애프터마켓에서 주가는 급락하고 있다. 실적 보고서의 요약 내용은 다음과 같다.

헬스에퀴티 4분기 EPS 예상치 미달, 부진한 전망...시간외 주가 15% 급락

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

BIDU

CWCO

GETY

SAIC

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#34;극단적 공포&#34; 영역에 머물렀다.미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 &#39;극단적 공포&#39; 영역

HealthEquity Inc

Keybanc analyst Scott Schoenhaus maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Overweight and lowers the price target from $110 to $100.

Price Target

Keybanc Maintains Overweight on HealthEquity, Lowers Price Target to $100

In the last three months, 8 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.5, a high estimate of $125.00, and a low estimate of $94.00. Marking an increase of 0.22%, the current average surpasses the previous average price target of $112.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372848_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $94.00&#x7C;$107.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $115.00&#x7C;$120.00 &#x7C; 
&#x7C;Scott Schoenhaus &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $110.00&#x7C;$120.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Stan Berenshteyn &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $125.00&#x7C;$110.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $120.00&#x7C;$105.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of HealthEquity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into HealthEquity's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Unveiling the Story Behind HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.24%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's ROA stands out, surpassing industry averages. With an impressive ROA of 0.76%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 8 Analysts

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and lowers the price target from $107 to $94.

Goldman Sachs Maintains Neutral on HealthEquity, Lowers Price Target to $94

AMGN

Live On CNBC, Karen Firestone Announces Bought More HealthEquity; Bought Amgen

Last week, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44386926/healthequity-stock-falls-after-reporting-q4-results-revenue-beat-eps-miss-soft-guidance" rel="noreferrer noopener">missing the consensus of 72 cents.</a>
Revenue increased 19% year over year to $311.8 million, beating the&nbsp;consensus of $306.05 million.
The health savings account (HSA) custodian reported adjusted EBITDA of $107.8 million, an increase of 9%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44403476/healthequity-stock-falls-on-weaker-than-expected-outlook-analyst-expects-better-margins-earnings-growth-in-later-2026-and-beyond" rel="noreferrer noopener">HealthEquity&#8217;s Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says</a>
In a note on Tuesday, analyst Gregory Peters writes that all financial institutions are dealing with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">elevated levels of fraud</a>.
HealthEquity stock&#8217;s recent year-to-date underperformance is partly due to its disclosure of fraud against some of its HSA customers and near-term investor concerns about recent management changes. The stock is inexpensive, and the analyst expects management to utilize the share repurchase program to capitalize on the weakness.
Despite reducing estimates for increased fraud-related costs, Raymond James upgraded HealthEquity to Strong Buy from Outperform.
The analyst lowered the price <a target="_blank" href="https://www.benzinga.com/quote/HQY/analyst-ratings" rel="noreferrer noopener">target from $120 to $115</a>.
&#8220;Longer term, we have a favorable outlook on the growing HSA market, HQY&#8217;s ability to gain market share, and HSA cash repricing at higher yields, which should lead to margin expansion and double-digit EPS growth over each of the next two years,&#8221; Raymond James analyst says.
The analyst writes that the stock has been outperforming peers and the market on a YTD basis due in part to some investors&#8217; flight to quality, the growing expectation for federal legislative improvements in the functionality of HSAs, and a reasonably stable interest rate outlook.
Price Action: HQY stock is up 0.75% at $91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44473580/mural-oncologys-ovarian-cancer-combo-drug-trial-disappoints-stock-plunges" target="_blank" rel="noreferrer noopener">Mural Oncology&#8217;s Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

General

HealthEquity Earns Stock Upgrade Despite Fraud Concerns

On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>). Avalo&#8217;s lead asset is AVTX-009, an anti-IL-1β mAb <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">targeting inflammatory diseases</a>.
The company initiated a Phase 2 LOTUS trial, which will include approximately 180 adults with hidradenitis suppurativa (HS), to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo. Topline data is <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44413131/avalo-reports-2024-financial-results-and-recent-business-updates" rel="noreferrer noopener">expected in 2026</a>.
Avalo continues to evaluate AVTX-009 for additional immune-mediated diseases with plans to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38278240/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-" rel="noreferrer noopener">announce a second indication</a>.
Analyst Alex Thompson writes that the following proof-of-concept data in HS from AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) lebrikizumab, an IL-1α/β bispecific success for AVTX-009, is highly de-risked given the strong evidence suggesting that IL-1β blockade represents the key driver of efficacy for Lutikizumab.
In January 2024, AbbVie&#8217;s Phase 2 results showed that adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981) 300 mg every other week or 300 mg weekly achieved higher response rates (59.5% nominal p=0.027 and 48.7%, nominal p=0.197, respectively) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/n36531984/lutikizumab-showed-positive-results-in-a-phase-2-trial-of-adults-with-moderate-to-severe-hidradeni" rel="noreferrer noopener">than placebo (35%)</a>.
Stifel writes that AVTX-009 can achieve comparable efficacy to lutikizumab albeit with the potential for superior dosing (Q4W vs. Q2W), equating to a meaningful minority share within the growing HS market yielding over $2 billion drug in the US alone amid significant strategic interest in the space.
Stifel has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/AVTX/analyst-ratings" rel="noreferrer noopener">price target of $36</a>.
&#8220;Bottomline we think AVTX represents an attractive HS pure-play with a favorable risk-reward heading into topline Ph2 data in the 2026 timeframe. Strong external HS newsflow over the next 12 months offers an additional tailwind,&#8221; Stifel analyst writes.
Cash and cash equivalents&nbsp;were $134.5 million as of December 31, 2024. The company&#8217;s current cash on hand is expected to fund operations into at least 2027.
Price Action: AVTX stock is up 15.5% at $8.81 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44473549/pony-ai-q4-revenue-slumps-nearly-30-as-robotaxi-sales-decline-loss-widens" target="_blank" rel="noreferrer noopener">Pony AI Q4: Revenue Slumps Nearly 30% As Robotaxi Sales Decline, Loss Widens</a></li>
</ul>

Biotech

Initiation

ABBV

AVTX

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Michael Halloran upgraded the rating for Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) from Neutral to Outperform and maintained the price target of $114. Pentair shares closed at $89.85 on Monday. <a href="https://www.benzinga.com/quote/PNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst C. Gregory Peters upgraded HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Outperform to Strong Buy but lowered the price target from $120 to $115. HealthEquity shares closed at $90.32 on Monday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Kevin Yin upgraded MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) from Neutral to Overweight and raised the price target from $15 to $22. MINISO Group shares closed at $18.35 on Monday. <a href="https://www.benzinga.com/quote/MNSO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Madeline Brooks upgraded the rating for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Underperform to Buy and raised the price target from $60 to $160. Cloudflare shares closed at $123.93 on Monday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Adam Jonas upgraded Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) from Equal-Weight to Overweight and boosted the price target from $260 to $280. Carvana shares closed at $213.63 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NET stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44472214/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

CVNA

MNSO

This Cloudflare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Raymond James analyst C. Gregory Peters upgrades HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) from Outperform to Strong Buy and lowers the price target from $120 to $115.

Raymond James Upgrades HealthEquity to Strong Buy, Lowers Price Target to $115

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 2.94% on an annualized basis producing an average annual return of 13.71%. Currently, HealthEquity has a market capitalization of $7.81 billion. 
Buying $1000 In HQY: If an investor had bought $1000 of HQY stock 10 years ago, it would be worth $3,618.59 today based on a price of $90.32 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742851815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In HealthEquity 10 Years Ago Would Be Worth This Much Today

Keybanc analyst Scott Schoenhaus maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Overweight and lowers the price target from $120 to $110.

Keybanc Maintains Overweight on HealthEquity, Lowers Price Target to $110

In the last three months, 4 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for HealthEquity, revealing an average target of $117.25, a high estimate of $125.00, and a low estimate of $112.00. Witnessing a positive shift, the current average has risen by 6.83% from the previous average price target of $109.75.
<img src="https://www.benzinga.com/files/images/story/2025/1742414451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to HealthEquity. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Get to Know HealthEquity Better</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>Understanding the Numbers: HealthEquity's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining HealthEquity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.55% as of 31 October, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.27%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: HealthEquity's debt-to-equity ratio is below the industry average at 0.53, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess HealthEquity: What You Need To Know

On Tuesday, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago, <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44386926/healthequity-stock-falls-after-reporting-q4-results-revenue-beat-eps-miss-soft-guidance" rel="noreferrer noopener">missing the consensus of 72 cents.</a>
Revenue increased 19% year over year to $311.8 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results" rel="noreferrer noopener">consensus of $306.05 million</a>.
The health savings account custodian reported adjusted EBITDA of $107.8 million, an increase of 9%.
Health savings accounts (HSAs) as of January&nbsp;31, 2025, were 9.9&nbsp;million, an increase of 14% year over year, including 753,000 HSAs with investments, an increase of 23% year over year. As of January&nbsp;31, 2025, total accounts were 17.0 million, including 7.1 million other consumer-directed benefits (CDBs).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
Guidance: HealthEquity expects fiscal year 2026 revenue of $1.28 billion to $1.305 billion, compared to estimates of $1.301 billion.
The company anticipates adjusted EPS of $3.57 to $3.74, compared to the consensus of $3.71. Management expects Adjusted EBITDA of $525 million to $545 million.
Barrington Research maintains HealthEquity with an <a target="_blank" href="https://www.benzinga.com/quote/HQY/analyst-ratings" rel="noreferrer noopener">Outperform and a $112 price target.</a>
Analyst Alexander Paris writes the earnings were impacted by excess costs associated with cyber-fraud prevention and reimbursements.
&#8220;While the magnitude of the excess costs associated with cybersecurity fraud and prevention was more than expected, we are &#8220;looking over the valley&#8221; to better margins and earnings growth in 2H/26 and beyond,&#8221; analyst Paris writes.
With HQY&#8217;s strong HSA business and higher cash yields expected in the coming years, the analyst writes that the company&#8217;s overall financial and operational performance will keep improving once temporary extra costs subside.
Price Action: HQY stock is down 18.9% at $82.46 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44394046/oracle-integrates-nvidia-ai-enterprise-and-secures-major-defense-cloud-deal-with-singapore" target="_blank" rel="noreferrer noopener">Oracle Integrates NVIDIA AI Enterprise and Secures Major Defense Cloud Deal with Singapore</a></li>
</ul>
Image via Shutterstock.

Equities

Reiteration

HealthEquity's Long-Term Growth Intact Despite Short-Term Margin Pressures, Analyst Says

<h3>Gainers</h3>
<ul>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million. </li>
<li>OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BDTX

CANF

HURA

INTS

LYEL

OABI

SCNX

TNXP

VERO

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 200 points on Wednesday.
The Dow traded up 0.55% to 41,808.59 while the NASDAQ climbed 0.95% to 17,671.26. The S&amp;P 500 also rose, gaining, 0.66% to 5,651.61.
Check This Out: <a href="https://www.benzinga.com/25/03/44396179/how-to-earn-500-a-month-from-jabil-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Jabil Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 1.2% on Wednesday.
In trading on Wednesday, real estate shares fell by 0.7%.
Top Headline
The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Service Properties Trust &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NASDAQ">SVC</a>) shares shot up 18% to $2.94 after Wells Fargo upgraded the stock from Underweight to Overweight and raised its price target from $2.5 to $4.</li>
<li>Shares of Aterian, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>)got a boost, surging 31% to $2.7640 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>BGM Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) shares were also up, gaining 16% to $11.79 after the company announced the acquisition of YX for $95 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares dropped 18% to $83.35 after the company reported worse-than-expected fourth-quarter adjusted EPS results.</li>
<li>Shares of Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) were down 30% to $0.2815 after the company announced a 1-for-12 reverse stock split.</li>
<li>OmniAb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) was down, falling 17% to $2.6545 following fourth-quarter earnings.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $67.38 while gold traded down 0.1% at $3,040.50.
Silver traded down 1.6% to $34.275 on Wednesday, while copper rose 1.2% to $5.0765.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.12%, Germany's DAX 40 fell 0.55% and France's CAC 40 gained 0.65%. Spain's IBEX 35 Index rose 0.30%, while London's FTSE 100 rose 0.08%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei falling 0.25%, China's Shanghai Composite Index falling 0.1%, Hong Kong's Hang Seng Index gaining 0.12% and India's BSE Sensex gaining 0.20%.
Economics
<ul>
<li>U.S. mortgage applications declined by 6.2% in the second week of March, following a cumulative 37% increase from the two prior weeks.</li>
<li>The EIA said crude oil inventories in the US increased by 1.745 million barrels in the week ended March 14, compared to market estimates of a 1.1 million gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>

Eurozone

Commodities

Intraday Update

ATER

ONVO

Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ABSI/earnings">worse-than-expected fourth-quarter financial results.</a>
Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This is unchanged from the same period last year. The company reported quarterly sales of $665.000 thousand which missed the analyst consensus estimate of $1.778 million.
Absci shares dipped 9.4% to $2.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares dipped 16.1% to $26.50 in pre-market trading after climbing 70% on Tuesday.</li>
<li>Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>) shares fell 14.8% to $6.43 in pre-market trading.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined 14.7% to $86.68 in pre-market trading after the company reported worse-than-expected quarterly earnings results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 13% to $17.87 in pre-market trading following weak quarterly sales.</li>
<li>Waterdrop Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) declined 6.5% to $1.30 in pre-market trading following a 5% fall on Tuesday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) declined 4.3% to $34.53 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) fell 3.8% to $5.63 in pre-market trading.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) fell 3.2% to $31.47 in pre-market trading after gaining 14% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Materials Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>
Photo: Shutterstock

ABSI

ATGL

RHLD

Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 45.4% to $2.93 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) stock moved upwards by 32.73% to $2.23. The company's market cap stands at $126.3 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares moved upwards by 22.55% to $2.88. The market value of their outstanding shares is at $113.4 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock rose 18.68% to $4.51. The market value of their outstanding shares is at $207.6 million. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock moved upwards by 17.58% to $1.07. The market value of their outstanding shares is at $16.4 million. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock increased by 12.41% to $0.65. The company's market cap stands at $18.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 19.9% to $0.36 during Wednesday's pre-market session. The company's market cap stands at $22.2 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock decreased by 18.52% to $2.86. The market value of their outstanding shares is at $386.7 million. </li>
<li>Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) shares decreased by 16.13% to $15.76. The market value of their outstanding shares is at $2.6 billion. </li>
<li>HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) shares declined by 15.61% to $85.8. The company's market cap stands at $7.4 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 14.88% to $26.9. The company's market cap stands at $350.0 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares fell 12.85% to $1.56. The market value of their outstanding shares is at $30.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

CRGX

IMVT

INNV

NXTC

OSRH

PASG

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

HealthEquity shares are trading lower after the company reported worse-than-expected Q4 Adj. EPS results.

U.S. stock futures advanced on Wednesday ahead of the Federal Open Market Committee&#8217;s (FOMC) decision on the interest rates. Futures of all four benchmark indices were higher in premarket trading.
On Tuesday, the stocks plunged after a two-day rally as the Magnificent 7 stocks dragged the indices down. Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GTC AI Conference failed to ignite a rally despite a slew of announcements.
The two-day FOMC meeting began on Tuesday, and the Federal Reserve Chairman Jerome Powell is expected to announce its decision during a press conference on Wednesday afternoon.
The 10-year Treasury yield stood at 4.29%, while the two-year yield was at 4.05%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 99% chance that the Federal Reserve will keep interest rates unchanged.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.16%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.26%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.28%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Wednesday. The SPY was up 0.26% to $562.46, and the QQQ advanced 0.35% to $476.22, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Technology, communication services, and consumer discretionary sectors led U.S. stock declines on Tuesday, with the Nasdaq Composite falling roughly 300 points.
Specifically, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) dropped about 4%, and Nvidia Corp. fell over 3%.
The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) also saw a decline exceeding 1%. In contrast, energy and healthcare stocks rose, defying the broader market&#8217;s downward trend.
Economic data showed that U.S. import prices increased by 0.4% in February, exceeding expectations, while export prices rose 0.1%. The U.S. industrial production also surpassed estimates, increasing by 0.7% in February.
The Nasdaq 100 index continues to be in the correction zone as it was still 12.33% lower from its previous high. While Dow Jones was 7.75% lower, S&amp;P 500 declined 8.67% from their respective 52-week highs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.71%</td>
<td>17,504.12 </td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.07%</td>
<td>5,614.66</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.62%</td>
<td>41,581.31</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.89%</td>
<td>2,049.94</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
"No rate change is expected," noted senior economist at WisdomTree, Jeremy Siegel ahead of the Federal Reserve&#8217;s decision, adding that the dot plot will be updated. The market is pricing in two rate cuts this year, he says, but he's "not convinced that the Fed will fully signal that just yet."
Furthermore, Siegel anticipates Powell will face intense scrutiny regarding declining market sentiment and inflation concerns.
He believes market direction hinges on the tariff situation; further escalation by President Donald Trump could trigger a significant downturn, potentially a &#8220;bear market&#8221;. Regarding Big Tech, Siegel argues current valuations, excluding Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), are high but not bubble-like, unlike the 2000 tech boom.
&#8220;For now, tariffs remain the dominant market force. The path forward depends on how Trump navigates trade policy—any softening would be bullish for equities, while continued escalation would put further downside pressure on stocks,&#8221; Siegel added.
&#8220;We don't expect any surprises at this week&#8217;s FOMC meeting, with the Fed likely holding the federal funds rate in the 4.25% to 4.5% range,&#8221; said Collin Martin, director, of fixed income strategy at the Schwab Center for Financial Research
&#8220;With growth concerns now making the most headlines, Fed Chairman Powell will likely be asked about the balance of risks given that all of the uncertainty out there could weigh on the labor market. We still expect rate cuts later this year, likely in the second half,&#8221; said Martin
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>FOMC will announce its decision on interest rates at 2:00 p.m., and Federal Reserve Chairman Jerome Powell will address a press conference at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) was up 0.31% in premarket on Wednesday ahead of its earnings before the opening bell. Analysts expect earnings of $6.25 per share on revenue of $2.33 billion.</li>
</ul>
<ul>
<li>Williams-Sonoma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) advanced 1.17% as Wall Street expects it to report earnings of $2.93 per share on revenue of $2.35 billion before the opening bell.</li>
</ul>
<ul>
<li>Five Below Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose 1.26% ahead of its earnings after the closing bell. Analysts expect earnings of $3.38 per share on revenue of $1.39 billion.</li>
</ul>
<ul>
<li>Healthequity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) slumped 13.09% after it posted downbeat earnings for its fourth quarter on Tuesday.</li>
</ul>
<ul>
<li>StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) jumped 8.02% after reporting better-than-expected fourth-quarter earnings and sales results.</li>
</ul>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) was 2.01% higher after it announced an AI server lineup with new Nvidia GPU support.</li>
</ul>
<ul>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 1.06% ahead of the second day of the GTC AI conference.</li>
</ul>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) climbed 2.96% after receiving approval for rolling out its first Robotaxi in California.</li>
</ul>
<ul>
<li>TEN Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) surged 33.63% after it announced that it would initiate a $1 million stock repurchase program on March 17, 2025, with no set end date, funded by operating cash and subject to market conditions.</li>
</ul>
<ul>
<li>5E Advanced Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>) plunged 20.72% after it announced a resale of up to 20.63 million common shares by stockholders; the company will receive no proceeds and will cover all the expenses.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.63% to hover around $66.33 per barrel.
The gold spot index was down by 0.12% to $3,030.36 per ounce. Its last record high was at $3,045.39 per ounce. The Dollar Index was up by 0.35% at the 103.608 level.
Asian markets closed mixed on Wednesday with China&#8217;s CSI 300, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex advancing in trade. Japan's Nikkei 225, and Australia's ASX 200 index declined. European markets were also mixed in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44392370/nvidia-destroys-420-billion-of-investor-wealth-since-deepseek-launch-valuation-hits-a-29-month-low-as-gtc-fails-to-ignite-stock">Nvidia Loses $420 Billion In Market Capitalization Since DeepSeek Launch, Valuation Hits A 29-Month Low As GTC Fails To Ignite Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Federal Reserve

FEAM

NVDA

PLTR

SMCI

TSLA

XHLD

US Stocks Likely To Open Higher Ahead Of FOMC Decision: 'Tariffs Remain The Dominant Market Force' Amid Rising Economic Uncertainty, Says Expert

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HealthEquity, Inc. - HQY

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation – HQY

HQY Investor News: Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

HealthEquity, Inc. Announcement: If You Have Suffered Losses in HealthEquity, Inc. (NASDAQ: HQY) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm Encourages HealthEquity, Inc. Investors to Inquire About Securities Class Action Investigation - HQY

HealthEquity's Expedited Claims Technology Wins Artificial Intelligence Excellence Awards

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Keybanc

Barrington Research

Goldman Sachs

Raymond James

Wells Fargo

수요일 아침 (현지 시간 기준) 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 시그넷 주얼러스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>)가 분기 실적을 주당 6.25달러, 매출을 23억 3천만 달러로 발표할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>의 데이터에 따르면, 시그넷의 주식은 시간외 거래에서 0.3% 상승한 48.42달러에 거래되었다.</li>
<li>애널리스트들은 윌리엄스-소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)가 분기 실적을 주당 2.93달러, 매출을 23억 5천만 달러로 발표할 것으로 예상하고 있다. 이 회사는 개장 전에 실적을 발표할 예정이다. 윌리엄스-소노마의 주식은 화요일에 1.6% 하락하여 172.28달러에 거래를 마쳤다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 화요일에 4분기 실적이 부진하다고 발표했다. 헬스에퀴티는 2026 회계연도 매출을 12억 8천만 달러에서 13억 5천만 달러로 예상하며, 이는 13억 1천만 달러에 대한 예상치와 일치한다. 이 회사는 연간 실적을 주당 3.57달러에서 3.74달러로 예상하며, 이는 주당 3.71달러에 대한 예상치와 일치합니다. 헬스에퀴티의 주식은 시간외 거래에서 13.7% 하락하여 87.75달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">여기에서 사전 시장 보도를 확인하세요</a>
<ul>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>)는 4분기 실적과 매출이 예상보다 좋았다고 보고했다. 스톤코의 주식은 시간외 거래에서 10.2% 상승하여 10.85달러에 거래되었다.</li>
<li>애널리스트들은 파이브 빌로우(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)가 분기 실적을 주당 3.38달러, 매출을 13억 9천만 달러로 발표할 것으로 예상하고 있다. 파이브 빌로우의 주식은 시간 외 거래에서 1.3% 상승하여 74.88달러에 거래되었다.</li>
</ul>
이것도 확인해보세요: <a href="https://www.benzinga.com/25/03/44375233/top-3-materials-stocks-which-could-rescue-your-portfolio-this-month">이달에 포트폴리오를 구해줄 수 있는 상위 3개 소재 주식</a>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일(18일) 장이 마감된 후 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 4분기 실적을 발표했고 애프터마켓에서 주가는 급락하고 있다. <a href="https://www.benzinga.com/pressreleases/25/03/g44384524/healthequity-reports-fiscal-year-and-fourth-quarter-ended-january-31-2025-financial-results" target="_blank" rel="noopener">실적 보고서</a>의 요약 내용은 다음과 같다.
<ul>
<li>4분기 매출: 3억 1,182만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener">예상치</a> 3억 605만 달러 상회</li>
<li>4분기 조정 주당순이익: 69센트, 예상치 72센트 하회</li>
</ul>
총 매출은 전년 동기 대비 19% 증가했다. 1월 31일 기준으로 990만 개의 건강저축계좌(HSA)가 개설되어 전년 대비 14% 증가했다. 1월 31일 기준 총 계좌 수는 1,700만 개를 기록했다. 총 HSA 자산은 전년 대비 27% 증가한 321억 달러였다.
헬스에퀴티는 2025회계연도에 보통주 140만 주를 1억 2,220만 달러에 재매입했다고 밝혔다. 1월 31일 기준으로 1억 7,780만 달러의 자사주 매입 잔액이 남아 있다.
헬스에퀴티 사장 겸 CEO인 스콧 커틀러(Scott Cutler)는 이렇게 말했다. &#8220;팀 퍼플(Team Purple)은 기록적인 매출과 전략적 이니셔티브 발전에서 큰 진전을 이루며 2025회계연도를 강력하게 마무리하여 2026회계연도에 대한 전망을 제공 할 수 있었다.&#8221;
"우리는 회원 우선의 안전한 모바일 경험에 중점을 두고 고객, 네트워크 파트너 및 회원을 위해 파트너십을 강화하고, 놀라운 경험을 제공하며, 회원 성과를 촉진하기 위한 3D 전략을 실행하고 있다."
가이던스: 헬스에쿼티는 2026회계연도 매출을 12억 8,000만~13억 5,000만 달러로 전망했으며, 예상치는 13억 1,000만 달러다. 연간 수익은 주당 3.57달러에서 3.74달러로 전망되며, 예상치는 주당 3.71달러다.
이러한 가이던스는 중간 지점에서 예상치보다 낮게 나왔으며, 이는 애프터마켓 주가에 부담을 주는 것으로 보인다.
HQY 주가 움직임: 주가는 화요일 애프터마켓에서 15.04% 하락한 86.38달러에 거래되고 있다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 정서에서 약간의 개선을 보여주었지만, 월요일에도 여전히 &#8220;극단적 공포&#8221; 영역에 머물렀다.
미국 주식은 월요일(17일)에 상승세를 보였으며, 다우존스 지수가 거래 중에 350포인트 이상 급등했다. 주요 지수 3개 모두 연속으로 상승했다.
월요일에 상승세를 나타냈음에도 불구하고, 미국 주식은 지난주 하락을 기록했다. 다우 지수는 약 3.1% 하락하여 2023년 3월 이후 최악의 주간 실적을 기록했고, S&amp;P 500은 2% 이상 하락하여 4주 연속 하락세를 나타냈다.
게스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) 주가는 회사가 WHP 글로벌로부터 주당 13달러 현금으로 회사를 인수하겠다는 비구속적 제안을 받았다고 발표한 후 월요일에 30% 급등했다. 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) 주가는 &#8216;어니 4.5&#8217; 및 딥씽킹 모델 &#8216;어니 X1&#8217;의 출시를 발표한 후 9% 상승했다.
경제지표 측면에서, 미국 소매판매는 2월에 전월 대비 0.2% 증가했으며, 시장 예상치 0.6% 상승에는 미치지 못했다. 단, 1월 소매판매는 1.2% 감소로 하향 수정되었다. NY 엠파이어 스테이트 제조업 지수는 3월에 26포인트 하락한 -20.0을 기록하며 2023년 5월 이후 최저치를 기록했다. NAHB/웰스파고 주택시장 지수는 3월에 39로 하락했으며, 2월에는 42를 기록했다.
S&amp;P 500 지수 대부분의 섹터는 월요일에 상승세를 보였고 특히 부동산, 에너지 및 필수소비재 섹터가 가장 큰 상승폭을 기록했다. 하지만 임의소비재 섹터는 시장 추세와 반대로 하락했다.
투자자들은 IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>), 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), 스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) 등의 실적 발표를 기다리고 있다.
다우존스는 월요일에 약 353포인트 상승하여 41,841.63포인트로 마감했다. S&amp;P 500은 0.64% 상승하여 5,675.12포인트로 상승했고, 나스닥 종합 지수는 월요일 거래 중 0.31% 상승하여 17,808.66포인트로 마감했다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 22.1로, 월요일에 &#8220;극단적 공포&#8221; 영역에 머물렀다. 이전 지수는 20.9였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock

긍정적 경제지표로 다우 지수 350p 상승: 투자자 불안 완화, 탐욕 지수는 '극단적 공포' 영역

화요일(18일) 미국 지수 선물이 하락세를 보이고 있는 가운데, 오늘 투자자의 주목을 받을 수 있는 주식은 다음과 같다.
<ul>
<li>IHS 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>): 화요일 개장 전 실적을 발표할 예정이며, 월가에서는 주당순이익 4센트, 매출 4억 2,400만 달러를 예상하고 있다. 주식은 월요일 애프터마켓에서 0.5% 상승하여 3.93달러에 거래되었다.</li>
<li>헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>): 화요일 장 마감 후 실적을 발표할 예정이며, 주당순이익 72센트와 매출 3억 6,605만 달러를 발표할 것으로 예상된다. 주식은 월요일 애프터마켓에서 1.1% 상승하여 101.87달러에 거래되었다.</li>
<li>게티 이미지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>): 월요일에 4분기 긍정적인 실적을 발표했다. 주식은 월요일 애프터마켓에서 0.9% 하락하여 2.1301달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>상가모 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>): 예상보다 저조한 4분기 재무 실적을 발표했다. 주식은 월요일 애프터마켓에서 3% 하락하여 0.98달러에 거래되었다.</li>
<li>스톤코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>): 장 마감 후 실적을 발표할 예정이며, 분기 주당순이익 35센트와 매출 6억 4,756만 달러를 발표할 것으로 예상한다. 주식은 월요일 애프터마켓에서 0.1% 상승하여 10.20달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

SGMO

화요일 주목해야 할 주식: IHS 홀딩, 헬스에퀴티, 게티 이미지, 상가모 테라퓨틱스 및 스톤코

금요일 미국 증시는 S&amp;P 500 지수가 장중 2% 이상 급등하면서 상승세로 마감했다.
금요일의 상승에도 불구하고 지난주 증시는 주간 하락을 기록했다. 다우지수는 약 3.1% 하락하며 2023년 3월 이후 최악의 한 주를 기록했고, S&amp;P 500 지수는 2% 이상 하락하며 4주 연속 하락세를 기록했다.
월가 애널리스트들은 매일 새로운 종목을 추천하지만, 안타깝게도 모든 애널리스트가 시장 움직임을 예측하는 데 특별히 인상적인 실적을 가지고 있는 것은 아니다. 하나의 주식에 대해서도 애널리스트 의견 등급과 목표주가가 천차만별이기 때문에 투자자들은 어떤 애널리스트의 의견을 믿어야 할지 혼란스러울 수 있다.
벤징가의 애널리스트 주식 등급은 벤징가 뉴스 데스크가 주요 셀사이드(sell-side) 은행과의 직접 제휴를 통해 선별한 최고 품질의 주식 등급을 모아 놓은 것이다. 벤징가는 미국 주식 시장이 개장하기 3시간 전에 매일 밤새 변경된 등급을 표시한다. 투자 대시보드 제공업체인 Toggle.ai의 데이터 전문가들은 최근 벤징가 프로 구독자와 벤징가 독자들이 정기적으로 받는 애널리스트 인사이트가 주식 시장수익률 상회를 위한 트레이딩 지표로 성공적으로 사용될 수 있다는 사실을 밝혀냈다.
<h2>최고 애널리스트의 추천</h2>
다행히도 벤징가 독자라면 누구나 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie" target="_blank" rel="noopener">애널리스트 주식 등급</a> 페이지에서 최신 애널리스트 평가에 액세스할 수 있다. 트레이더가 벤징가의 방대한 애널리스트 주식 등급 데이터베이스를 정렬할 수 있는 방법 중 하나는 애널리스트 정확도이다. 벤징가 <a href="https://www.benzinga.com/analyst-stock-ratings" target="_blank" rel="noopener">애널리스트 주식 평가</a>에 따르면 가장 정확한 월가 애널리스트 5명이 가장 최근에 추천한 종목을 살펴보자.
애널리스트: 트레버 왈시(Trevor Walsh)
<ul>
<li>애널리스트 회사: 시티즌즈 캐피털 마켓츠</li>
<li>평가 정확도: 85%</li>
<li>최신 평가: 3월 14일, 로켓랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 시장수익률 등급 재확인</li>
<li>최근 뉴스: 3월 15일에 로켓랩은 바르다 스페이스 인더스트리(Varda Space Industries, Inc.)를 위한 세 번째 파이오니어(Pioneer) 우주선이 궤도에서 성공적으로 작동하고 있다고 발표했다.</li>
</ul>
애널리스트: 마크 휴즈(Mark Hughes)
<ul>
<li>애널리스트 회사: 트루이스트 증권</li>
<li>평가 정확도: 83%</li>
<li>최신 평가: 3월 11일, 제임스 리버 그룹 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>)에 대해 보유 등급을 유지하고 목표주가를 6달러에서 5달러로 하향 조정. 주식이 약 25% 급등할 것으로 예상.</li>
<li>최근 뉴스: 3월 4일 제임스 리버 그룹은 4분기 EPS 결과가 예상보다 저조하게 나타났다고 보고했다.</li>
</ul>
애널리스트: 롭 오웬스(Rob Owens)
<ul>
<li>애널리스트 회사: 파이퍼 샌들러</li>
<li>평가 정확도: 82%</li>
<li>최신 평가: 3월 13일, 센티넬원(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>)에 대해 비중확대 등급을 유지하고 목표주가를 32달러에서 28달러로 하향 조정. 주식이 52% 상승할 것으로 예상.</li>
<li>최근 뉴스: 3월 12일, 센티넬원은 4분기 매출이 2억 2,550만 달러로, 컨센서스 추정치인 2억 2,225만 달러를 초과했다고 발표했다.</li>
</ul>
애널리스트: 애론 레이커스(Aaron Rakers)
<ul>
<li>애널리스트 회사: 웰스파고</li>
<li>평가 정확도: 82%</li>
<li>최신 평가: 3월 13일, 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)에 대해 비중확대 등급을 유지하고 목표주가를 140달러에서 130달러로 하향 조정. 주식이 약 29% 상승할 것으로 예상.</li>
<li>최근 뉴스: 3월 5일, 마이크론은 마크 리우(Mark Liu)와 크리스티 시몬스(Christie Simons)를 이사회에 임명했다.</li>
</ul>
애널리스트: 알렉산더 패리스(Alexander Paris)
<ul>
<li>애널리스트 회사: 배링턴 리서치</li>
<li>평가 정확도: 81%</li>
<li>최신 평가: 3월 14일, 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)에 대해 시장수익률 상회폼등급을 유지하고 목표주가를 112달러로 설정. 주식이 약 15% 상승할 것으로 예상.</li>
<li>최근 뉴스: 2월 18일, 헬스에퀴티는 2025회계연도와 2026회계연도 가이던스를 확정했다.</li>
</ul>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

JRVR

RKLB

월가에서 가장 정확한 애널리스트의 지난주 추천 주식 5종목

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 헬로 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>)이 개장 전에 3억 7,252만 달러의 매출과 주당 28센트의 분기 이익을 보고할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면, 헬로 그룹의 주가는 시간외 거래에서 0.6% 하락한 6.60달러를 기록했다.
2. 분석가들은 Z스케일러(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)가 5억 6,793만 달러의 매출과 주당 69센트의 분기 이익을 기록할 것으로 예상한다. 회사는 시장이 마감된 후 실적을 발표할 예정이다. Z스케일러의 주식은 시간외 거래에서 0.1% 상승한 200.00달러를 기록했다.
3. 앱토즈 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>)의 주식은 회사가 한미약품(Hanmi Pharmaceutical Co.)와의 시설 계약을 통해 1천만 달러의 대출을 발표한 후 금요일 애프터마켓에서 상승했다. 앱토즈의 주식은 애프터마켓에서 69.3% 급등하여 0.6874달러에 거래되고 있다.
프리마켓 보도를 <a href="https://www.benzinga.com/premarket/">여기에서 확인하세요</a>
4. 시장이 마감된 후 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 매출 2억 8,487만 달러에 주당 70센트의 분기 이익을 게시할 것으로 예상된다. 헬스에퀴티의 주가는 시간외 거래에서 0.6% 하락한 79.10달러를 기록했다.
5. 애널리스트들은 스포츠맨스 웨어하우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>)가 마감 후 2억 8,503만 달러의 매출과 주당 9센트의 분기 손실을 보고할 것으로 예상한다. 스포츠맨스 웨어하우스의 주가는 시간외 거래에서 1% 하락한 2.08달러를 기록했다.
이것도 확인해 보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">이번 분기에 폭발적으로 성장할 수 있는 2개 부동산 주식</a></li>
</ul>
AI 도구를 사용하여 생성한 이미지
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

APTO

MOMO

SPWH

화요일 주목해야 할 주식: 헬로 그룹, Z스케일러, 앱토즈 그리고 2종목

헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)는 회사가 월요일 1분기 재무 결과를 발표한 후 주가가 상승했다. <a href="https://www.benzinga.com/pressreleases/24/06/g39145596/healthequity-reports-first-quarter-ended-april-30-2024-financial-results" target="_blank" rel="noopener">이 보고서</a>의 주요 내용을 살펴보자.
중요한 사항 (The Details): 헬스에퀴티는 분기별 주당 이익을 80센트로 보고했는데, 이는 애널리스트들의 합의 추정치인 66센트를 21.21% 상회했으며, 지난해 같은 기간보다 주당 이익인 50센트보다 60% 증가한 수치이다.
분기별 매출은 2억 8,760만 달러로 분석가 컨센서스 추정치인 2억 7,811만 달러를 넘어섰고, 이는 지난해 같은 기간의 매출 2억 4,443만 달러보다 17.66% 증가한 수치이다.
이 회사에 따르면 매출은 서비스 매출 1억1,820만 달러, 보관 매출 1억2,160만 달러, 교차 매출 4,770만 달러로 구성됐다. 2024년 4월 30일 현재 HSA는 910만 개로 전년 대비 13% 증가했으며, 여기에는 투자가 포함된 665,000개의 HSA가 포함되어 전년 대비 20% 증가했다. 2024년 4월 30일 기준 총 계정 수는 1,600만 개이며, 기타 소비자 지향 혜택 690만 개를 포함한다.
헬스에퀴티의 사장 겸 CEO인 존 케슬러(Jon Kessler)는 "기록적인 1분기 HSA 매출, 향상된 요금 적용 확대, 훌륭한 팀을 위한 베네핏월렛(BenefitWallet) 트랜치 3개 중 2개의 적시 전환이 2025 회계연도에 시작된다"고 말했다.
&#8220;성장과 마진 모두에 대한 추진력을 바탕으로 우리는 연간 지침을 높이고 놀라운 경험을 제공하고 파트너십을 심화하며 회원 성과를 높이기 위해 플랫폼 투자를 추진하고 있다.&#8221;
전망 (Outlook): 헬스에퀴티는 회계연도 이익을 주당 추정치 2.90달러 대비 주당 2.93~3.10달러로 전망하고, 회계연도 매출을 추정치 11억 6천만 달러 대비 11억 6천만~11억 8천만 달러로 예상한다.
HQY 주가 움직임: <a href="https://www.benzinga.com/stock/HQY#NASDAQ">Benzinga Pro</a>에 따르면, 이 회사의 주가는 월요일 시간외 거래에서 4.04% 상승한 84.50달러를 기록했다.

헬스에퀴티: 예상보다 좋은 제1분기 실적과 강력한 전망 발표 후 주가 상승

월요일 아침(현지 시간) 미국 주식 선물이 상승면서, 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">Benzinga Pro</a>의 데이터에 따르면 월스트리트는 사이언스 애플리케이션 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NYSE">SAIC</a>)가 개장 전에 분기별 이익을 주당 1.92달러, 매출 18억 4천만 달러로 보고할 것으로 예상하고 있다. SAIC 주식은 시간외 거래에서 3.4% 상승한 139.20달러를 기록했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)는 이사회 구성원인 엘리자베스 라파엘(Elizabeth Rafael)을 임시 CFO로 임명하고 1분기에 강력한 예비 결과를 발표했다. 이 회사는 시장 추정치인 주당 1.74달러에 비해 주당 1.87달러의 잠정 이익을 올렸고, 매출은 기대치인 13억 9,000만 달러에 비해 14억 2,000만 달러를 기록했다. 오토데스크의 주가는 시간외 거래에서 7.2% 상승한 216.04달러를 기록했다.</li>
<li>분석가들은 헬스에퀴티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>)가 2억 7,811만 달러의 매출과 주당 66센트의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 실적을 발표할 예정이다. 헬스에퀴티의 주식은 시간외 거래에서 1.4% 상승한 82.79달러를 기록했다.</li>
</ul>
저희는 여기에서 <a href="https://www.benzinga.com/premarket/">개장 전 시장 정보를 확인하세요</a>
<ul>
<li>밍주 로지스틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>)는 옥실러스 글로벌(Oxylus Global) 인수에 합의했다고 발표했다. 밍주 로지스틱스의 주가는 시간외 거래에서 66.6% 급등한 0.5667달러를 기록했다.</li>
<li>분석가들은 라보로(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>)가 시장 마감 후 6억 1,907만 달러의 매출과 주당 3센트의 분기 이익을 기록할 것으로 예상합니다. 라보로의 주가는 시간외 거래에서 3.5% 하락한 5.77달러를 기록했다.</li>
</ul>
다음 읽기: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39111222/over-8m-bet-on-this-health-care-stock-check-out-these-4-stocks-insiders-are-buying">이 헬스케어 주식에 800만 달러 이상을 베팅하시겠습니까? 내부자들이 구매하고 있는 4가지 주식을 확인하세요.</a>

ADSK

LVRO

YGMZ

사이언스 애플리케이션, 오토데스크 그리고 월요일 주목해야 할 주식 3종목

Comments

HealthEquity

뉴스

에 대한 최신 뉴스 HealthEquity (NASDAQ:HQY) 주식

수요일, 3월 19, 2025

화요일, 3월 18, 2025

월요일, 3월 17, 2025

화요일, 9월 03, 2024

월요일, 6월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌